Integra Lifesciences Q4 Adjusted EPS $0.89 Misses $0.90 Estimate, Sales $397.04M Miss $399.34M Estimate
Portfolio Pulse from Benzinga Newsdesk
Integra Lifesciences (NASDAQ:IART) reported Q4 adjusted EPS of $0.89, missing the $0.90 estimate, and sales of $397.04M, missing the $399.34M estimate. This represents a decrease in both earnings and sales compared to the same period last year.
February 28, 2024 | 11:03 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Integra Lifesciences reported a slight miss in both Q4 earnings and sales compared to analyst estimates, indicating a year-over-year decline.
Missing both earnings and sales estimates, even by small margins, can lead to negative investor sentiment in the short term. The year-over-year decline in both metrics further compounds concerns about the company's growth trajectory.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100